Oncology

Biopharmaceutical NCE's expand oncology franchise

Published in Cancer Weekly, December 23rd, 2003

EntreMed, Inc. (NASDAQ:ENMD), a biopharmaceutical company focusing on the research and development of small molecule therapeutics, has released preclinical analog data on one of its New Chemical Entities (NCEs) programs.

Using various analytical methods, EntreMed scientists designed and synthesized modifications of the structure of 2-methoxyestradiol (2ME2) to create NCEs with enhanced antitumor and antiangiogenic activities in in vitro models.

EntreMed scientists are now advancing the lead compounds into preclinical in vivo testing with the goal of identifying an IND candidate in oncology.

EntreMed President and Chief Operating...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry